- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07795385
Embodied Conversational Agents for Cervical Cancer Screening Abnormalities (ECA-CCSA)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: ECA-CCSA Research Coordinator
- Phone Number: 617-636-2229
- Email: saramyhealthnav@tuftsmedicine.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria: age 21-65, has an abnormal cervical cancer screening test result,
Exclusion Criteria: not able to read in English or Spanish, does not have adequate vision or hearing to use the app, planning to move out of the study area during the follow up period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Control
Standard of care only
|
|
|
Experimental: Conversational agent only
Receives conversational agent to provide personalized education
|
People receiving the intervention will receive an animated health coach that works on a smartphone to guide them through the cervical cancer screening and care process to ensure they receive the follow up and treatment they need to prevent cancer.
|
|
Experimental: conversational agent and advocacy
Receives conversational agent to provide personalized education and also guidance on talking to family and friends about cancer screening
|
People receiving the intervention will receive an animated health coach that works on a smartphone to guide them through the cervical cancer screening and care process to ensure they receive the follow up and treatment they need to prevent cancer.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
receipt of diagnostic evaluation
Time Frame: 18 months
|
18 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Perkins, Tufts Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 00006533
- 1R01CA296021-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
ACCESS, DISTRIBUTION, OR REUSE CONSIDERATIONS Data will be shared under a two-tier distribution system. All data that can be de-identified will be publicly shared. Data with specific confidentially risks, such as transcripts of interviews will not be shared publicly because of the difficulty masking the identity of participants. Data with increased risk of reidentification will be shared under a data-use agreement that clearly establish use rules to facilitate respondent confidentiality
WHETHER ACCESS TO SCIENTIFIC DATA WILL BE CONTROLLED
De-identified data will be freely available on the repository website. Restricted data (I.e., de-identified transcripts of interviews) will be available through a data use agreement. Data use agreements providing access to sensitive data will be managed by the repository of record.
PROTECTIONS FOR PRIVACY, RIGHTS, AND CONFIDENTIALITY OF HUMAN RESEARCH PARTICIPANTS
In order to ensure participant consent for data sharing, IRB paperwork and informed
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.